Ovid Therapeutics Inc. income statement

In fiscal 2025, Ovid Therapeutics Inc. reported revenue of $7.3m, up 1181.3% on the year before, operating income of −$42.4m (a -585.2% margin) and net income of −$17.4m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ovid Therapeutics Inc.: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	13	208	2	0	1	7	2
Research and development	63	47	25	29	37	26	34
General and administrative	31	37	32	31	26	24	26
Operating income	−81	124	−56	−59	−62	−42	−58
Income before tax	−81	124	−54	−52	−26	−17	−34
Income tax	0	1	0	0	0	0	0
Net income	−81	123	−54	−52	−26	−17	−34
Diluted EPS	−$1.39	$1.76	−$0.77	−$0.74	—	—	—
Diluted shares (average)	58m	68m	70m	71m	—	—	—
EBITDA	−81	124	−55	−59	−61	−42	−58

US$ millions unless shown otherwise. Fiscal quarters.

Ovid Therapeutics Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	0	0	6	0	1	0	1
Research and development	8	6	7	6	6	7	11	10
General and administrative	6	5	6	5	7	6	7	6
Operating income	−13	−11	−13	−5	−13	−12	−18	−16
Income before tax	−14	−9	−10	−5	−12	10	−17	−15
Income tax	0	0	0	0	0	0	0	0
Net income	−14	−9	−10	−5	−12	10	−17	−15
Diluted EPS	−$0.20	—	—	—	—	—	—	—
EBITDA	−13	−11	−12	−5	−13	−12	−18	−16

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABSI vs OVID OVID vs RNAC DARE vs OVID MCRB vs OVID

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ovid Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ovid Therapeutics Inc.